Log in to search using one of your social media accounts:

 

An information film to promote informed decision-making for a lung cancer screening
As lung cancer screening is a relatively new area, particularly to non-healthcare professionals, understanding of the procedure and risks involved are generally not well understood. Here, Mamta Rupare... Author: VJOncology Added: 02/23/2018 (Source: Oncology Tube)
Source: Oncology Tube - February 23, 2018 Category: Cancer & Oncology Source Type: podcasts

VEGF is Immunomodulatory & Decreases Regulatory T-Cell Responses Significant progress in the field of combining VEGF+TKI with immunotherapy
Tian Zhang, MD Duke University Medical Center, VEGF is Immunomodulatory & Decreases Regulatory T-Cell Responses Significant progress in the field of combining VEGF+TKI with immunotherapy at Kidney Ca... Author: kidneycancer Added: 02/22/2018 (Source: Oncology Tube)
Source: Oncology Tube - February 23, 2018 Category: Cancer & Oncology Source Type: podcasts

Geographic Outcomes of Metastatic RCC in Canada & Europe ESMO-MCBS shows real world data of the availability of new drugs
Aly-Khan Lalani, MD Dana Farber Cancer Institute, discusses Geographic Outcomes of Metastatic RCC in Canada & Europe ESMO-MCBS shows real world data of the availability of new drugs at Kidney Cancer ... Author: kidneycancer Added: 02/22/2018 (Source: Oncology Tube)
Source: Oncology Tube - February 23, 2018 Category: Cancer & Oncology Source Type: podcasts

Impact of Geographic Region in Clinical Outcome of Metastatic RCC The overall & progression-free survival seem similar across geographic regions
Andr P Fay, MD Hospital Me De Deus Cancer Institute, discusses Impact of Geographic Region in Clinical Outcome of Metastatic RCC The overall & progression-free survival seem similar across geographi... Author: kidneycancer Added: 02/22/2018 (Source: Oncology Tube)
Source: Oncology Tube - February 23, 2018 Category: Cancer & Oncology Source Type: podcasts

Many VEGF Phase 3 Trials Have Completed Accrual Colleagues can visit clinicaltrials.gov to see which are currently accruing
Tian Zhang, MD Duke University Medical Center, discusses Many VEGF Phase 3 Trials Have Completed Accrual Colleagues can visit clinicaltrials.gov to see which are currently accruing at Kidney Cancer A... Author: kidneycancer Added: 02/22/2018 (Source: Oncology Tube)
Source: Oncology Tube - February 22, 2018 Category: Cancer & Oncology Source Type: podcasts

Physician-Directed Patient-Oriented Improvements How physicians can deliver the best care & cost-intensive but still deliver value
Robert Uzzo, MD Fox Chase Cancer Center, discusses Physician-Directed Patient-Oriented Improvements How physicians can deliver the best care & cost-intensive but still deliver value at Kidney Cancer A... Author: kidneycancer Added: 02/22/2018 (Source: Oncology Tube)
Source: Oncology Tube - February 22, 2018 Category: Cancer & Oncology Source Type: podcasts

Canada Negotiates Drug Prices w Pan-Canadian Consortium Sunitinib & Pazopanib are most commonly prescribed off trial settings
Aly-Khan Lalani, MD Dana Farber Cancer Institute, discusses Canada Negotiates Drug Prices w Pan-Canadian Consortium Sunitinib & Pazopanib are most commonly prescribed off trial settings at Kidney Can... Author: kidneycancer Added: 02/22/2018 (Source: Oncology Tube)
Source: Oncology Tube - February 22, 2018 Category: Cancer & Oncology Source Type: podcasts

Early Phase VEGF Trials Enhance Responses in the 1st Line Could lead to improved outcomes of progression-free & overall survival
Tian Zhang, MD Duke University Medical Center, discusses Early Phase VEGF Trials Enhance Responses in the 1st Line Could lead to improved outcomes of progression-free & overall survival at Kidney Can... Author: kidneycancer Added: 02/22/2018 (Source: Oncology Tube)
Source: Oncology Tube - February 22, 2018 Category: Cancer & Oncology Source Type: podcasts

Economic Research and Value in Kidney Cancer Value incentivizes provider & delivery of high value quality-based care
Robert Uzzo, MD Fox Chase Cancer Center, discusses Economic Research and Value in Kidney Cancer Value incentivizes provider & delivery of high value quality-based care at Kidney Cancer Association 201... Author: kidneycancer Added: 02/22/2018 (Source: Oncology Tube)
Source: Oncology Tube - February 22, 2018 Category: Cancer & Oncology Source Type: podcasts

Sunitinib V. Pazopanib in the First Line Setting Patients receiving sunitinib had better overall survival
Aly-Khan Lalani, MD Dana Farber Cancer Institute, discusses Sunitinib V. Pazopanib in the First Line Setting Patients receiving sunitinib had better overall survival at Kidney Cancer Association 201... Author: kidneycancer Added: 02/22/2018 (Source: Oncology Tube)
Source: Oncology Tube - February 22, 2018 Category: Cancer & Oncology Source Type: podcasts

Is Durvalumab (Imfinzi) in Stage III NSCLC Curing Patients or Just Treating Metastatic Disease Earlier? Importance of Overall Survival and Implications for Duration of Treatment (BMIC-025)
Dr. Jack West explores the importance of following the overall survival of patients on the PACIFIC trial and considers still open questions of whether consolidation durvalumab (Imfinzi) in stage III u... Author: BeaconMedIC Added: 02/22/2018 (Source: Oncology Tube)
Source: Oncology Tube - February 22, 2018 Category: Cancer & Oncology Source Type: podcasts

Patient Power Message to OncologyTube Viewers
For years, Patient Power has made its rich library of video content for people living with cancer and their loved ones available on OncologyTube.com. Now, so that you can access all the features and s... Author: patientpower Added: 02/22/2018 (Source: Oncology Tube)
Source: Oncology Tube - February 22, 2018 Category: Cancer & Oncology Source Type: podcasts

Transforming Care After Treatment (TCAT): technology in the delivery of supportive care to lung cancer patients
Following cancer treatment, it is important to support and enable an increasing number of cancer survivors to live as healthy a life as possible for as long as possible. In this interview, Pamela Rose... Author: VJOncology Added: 02/22/2018 (Source: Oncology Tube)
Source: Oncology Tube - February 22, 2018 Category: Cancer & Oncology Source Type: podcasts

Next steps for an innovative electronic holistic care needs assessment tool in Scotland for cancer patients
Following the promising results of initial investigations into the use of an electronic healthcare assessment tool in the delivery of supportive care to lung cancer patients, the tool is going to cont... Author: VJOncology Added: 02/22/2018 (Source: Oncology Tube)
Source: Oncology Tube - February 22, 2018 Category: Cancer & Oncology Source Type: podcasts

Technology in the supportive care of lung cancer patients: patient preference and impact on time efficiency
Integrating technology into healthcare service delivery can improve patient experience whilst improving efficiency. In this interview, Pamela Rose, Macmillan Lung Cancer Clinical Nurse Specialist, of ... Author: VJOncology Added: 02/22/2018 (Source: Oncology Tube)
Source: Oncology Tube - February 22, 2018 Category: Cancer & Oncology Source Type: podcasts

An information film to promote informed decision-making for a lung cancer screening
As lung cancer screening is a relatively new area, particularly to non-healthcare professionals, understanding of the procedure and risks involved are generally not well understood. Here, Mamta Rupare... Author: VJOncology Added: 02/22/2018 (Source: Oncology Tube)
Source: Oncology Tube - February 22, 2018 Category: Cancer & Oncology Source Type: podcasts

APL: getting the perfect picture
Disease monitoring is important to determine what is happening with patients outside of the clinical setting. Speaking from the American Society of Hematology (ASH) 2017 Annual Meeting and Exposition ... Author: VJHemOnc Added: 02/22/2018 (Source: Oncology Tube)
Source: Oncology Tube - February 22, 2018 Category: Cancer & Oncology Source Type: podcasts

Targeted treatments for AML: the revolution
Exciting advancements in acute myeloid leukemia (AML) research were discussed during the American Society of Hematology (ASH) 2017 Annual Meeting and Exposition, held in Atlanta, GA. There has recentl... Author: VJHemOnc Added: 02/22/2018 (Source: Oncology Tube)
Source: Oncology Tube - February 22, 2018 Category: Cancer & Oncology Source Type: podcasts

Advancements in APL treatment: oral ATO, MRD and treatment objectives
Despite the remarkable progress being made in the treatment of patients with acute promyelocytic leukemia (APL), a high rate of early death remains a major obstacle worldwide, particularly in developi... Author: VJHemOnc Added: 02/22/2018 (Source: Oncology Tube)
Source: Oncology Tube - February 22, 2018 Category: Cancer & Oncology Source Type: podcasts

Novel ALL treatment strategies: CAR T-cells
CAR T-cells are a universally exciting area in hematological oncology. Speaking from the American Society of Hematology (ASH) 2017 Annual Meeting and Exposition in Atlanta, GA, Elias Jabbour, MD, of t... Author: VJHemOnc Added: 02/22/2018 (Source: Oncology Tube)
Source: Oncology Tube - February 22, 2018 Category: Cancer & Oncology Source Type: podcasts

Novel ALL treatment strategies: inotuzumab ozogamicin
Over the past year, several exciting new agents for the treatment of acute lymphoblastic leukemia (ALL) have been approved. In this interview, Elias Jabbour, MD, of the University of Texas MD Anderson... Author: VJHemOnc Added: 02/22/2018 (Source: Oncology Tube)
Source: Oncology Tube - February 22, 2018 Category: Cancer & Oncology Source Type: podcasts

Novel ALL treatment strategies: blinatumomab
There have recently been a number of major drug approvals for the treatment of acute lymphoblastic leukemia (ALL). One such approval was that of blinatumomab based on data from pivotal studies, includ... Author: VJHemOnc Added: 02/22/2018 (Source: Oncology Tube)
Source: Oncology Tube - February 22, 2018 Category: Cancer & Oncology Source Type: podcasts

Understanding the mechanisms of venetoclax and ibrutinib resistance
We need to understand the mechanisms of drug resistance in order to prevent it, in addition to informing subsequent treatment decisions. In this interview, Constantine Tam, MD, FRACP, FRCPA, of Peter ... Author: VJHemOnc Added: 02/22/2018 (Source: Oncology Tube)
Source: Oncology Tube - February 22, 2018 Category: Cancer & Oncology Source Type: podcasts

Durvalumab (Imfinzi) FDA Approved for Stage III NSCLC: Should It Become Standard of Care Without Overall Survival Benefit Demonstrated? (BMIC-024)
Dr. Jack West reviews key results of the PACIFIC trial of the immunotherapy agent durvalumab (Imfinzi) vs. placebo in stage III NSCLC and explains the pros and cons of durvalumab as a new standard of ... Author: BeaconMedIC Added: 02/20/2018 (Source: Oncology Tube)
Source: Oncology Tube - February 20, 2018 Category: Cancer & Oncology Source Type: podcasts

Rationale and results behind the use of breakthrough therapy-designated E-selectin antagonist for AML
The binding of E-selectin to leukemic cells has been shown to promote cell survival and chemotherapy resistance in acute myeloid leukemia (AML). In this interview, Daniel DeAngelo, MD, PhD, of Dana-Fa... Author: VJHemOnc Added: 02/20/2018 (Source: Oncology Tube)
Source: Oncology Tube - February 20, 2018 Category: Cancer & Oncology Source Type: podcasts

Complete remission seen in advanced systemic mastocytosis with avaritinib
The majority of patients with advanced systemic mastocytosis (AdvSM) exhibit D816V mutations of the KIT gene, which presents a promising therapeutic target. Here, Daniel DeAngelo, MD, PhD, of Dana-Far... Author: VJHemOnc Added: 02/20/2018 (Source: Oncology Tube)
Source: Oncology Tube - February 20, 2018 Category: Cancer & Oncology Source Type: podcasts

Whats next for inotuzumab ozogamicin in ALL?
The anti-CD22 antibody-drug conjugate inotuzumab ozogamicin was approved for the treatment of B-cell precursor acute lymphoblastic leukemia (ALL), the most common form of ALL, based on data from the I... Author: VJHemOnc Added: 02/20/2018 (Source: Oncology Tube)
Source: Oncology Tube - February 20, 2018 Category: Cancer & Oncology Source Type: podcasts

A next-generation CD33-directed ADC for AML
Next-generation antibody-drug conjugates (ADCs) are demonstrating improved safety and tolerability compared with their predecessors. Speaking from the American Society of Hematology (ASH) 2017 Annual ... Author: VJHemOnc Added: 02/20/2018 (Source: Oncology Tube)
Source: Oncology Tube - February 20, 2018 Category: Cancer & Oncology Source Type: podcasts

The evolving role of the Clinical Research Nurse and the Clinical Nurse Specialist in clinical trials
With the increasing complexity of clinical trials, the role of the Clinical Research Nurse (CRN) and the Clinical Nurse Specialist (CNS) continues to evolve. In this interview, recorded at the 2017 Na... Author: VJOncology Added: 02/20/2018 (Source: Oncology Tube)
Source: Oncology Tube - February 20, 2018 Category: Cancer & Oncology Source Type: podcasts

Nurses and recognizing each others work pressures
Staff within the NHS are very busy and work pressures can result in less time for communication between nurses. In this interview, Anne Croudass, Lead Research Nurse at Cancer Research UK (CRUK), Lond... Author: VJOncology Added: 02/20/2018 (Source: Oncology Tube)
Source: Oncology Tube - February 20, 2018 Category: Cancer & Oncology Source Type: podcasts

The nurses role in improving the clinical trial experience of patients
What can be done to improve the experience of clinical trials for patients who participate? In this interview, recorded at the 2017 National Cancer Research Institute (NCRI) Conference, held in Liverp... Author: VJOncology Added: 02/20/2018 (Source: Oncology Tube)
Source: Oncology Tube - February 20, 2018 Category: Cancer & Oncology Source Type: podcasts

Meeting in the box: working out the best practice strategies for HCPs and patients
Different NHS trusts work in different ways; what could be considered the best practice in one trust may not be practical in another. In this interview, recorded at the 2017 National Cancer Research I... Author: VJOncology Added: 02/20/2018 (Source: Oncology Tube)
Source: Oncology Tube - February 20, 2018 Category: Cancer & Oncology Source Type: podcasts

New therapeutic targets in CLL: ROR1
The identification of novel therapeutic targets is essential for the improved treatment of hematological cancer, particularly due to the development of drug resistance. Here, Constantine Tam, MD, FRAC... Author: VJHemOnc Added: 02/19/2018 (Source: Oncology Tube)
Source: Oncology Tube - February 19, 2018 Category: Cancer & Oncology Source Type: podcasts

CAR T-cells for CLL: ibrutinib pre-treatment, T-cell quality and future predictions
We know that CAR T-cell therapy is effective in the treatment of chronic lymphocytic leukemia (CLL); however, a current limitation is the collection of high quality originator T-cells from patients. S... Author: VJHemOnc Added: 02/19/2018 (Source: Oncology Tube)
Source: Oncology Tube - February 19, 2018 Category: Cancer & Oncology Source Type: podcasts

Cessation of venetoclax and remaining in remission from CLL?
There is not a large amount of data available to allow clinicians to determine whether patients should remain on or cease venetoclax treatment. In this interview, Constantine Tam, MD, FRACP, FRCPA, of... Author: VJHemOnc Added: 02/19/2018 (Source: Oncology Tube)
Source: Oncology Tube - February 19, 2018 Category: Cancer & Oncology Source Type: podcasts

Pembrolizumab: defining standards of care in urothelial cancer
Following the completion of the initial stages of the KEYNOTE-045 trial of pembrolizumab vs. the standard care for advanced urothelial cancer following chemotherapy (NCT02256436), clinicians have been... Author: VJOncology Added: 02/19/2018 (Source: Oncology Tube)
Source: Oncology Tube - February 19, 2018 Category: Cancer & Oncology Source Type: podcasts

TKI and checkpoint inhibitor combinations for kidney cancer: the IMmotion151 trial
The current standard of care for frontline kidney cancer is tyrosine kinase inhibitor (TKI) treatment. Now there are a host of promising immune checkpoint inhibitors in trials for this indication, eit... Author: VJOncology Added: 02/19/2018 (Source: Oncology Tube)
Source: Oncology Tube - February 19, 2018 Category: Cancer & Oncology Source Type: podcasts

Promising POUT: perioperative chemotherapy for upper tract urothelial cancer
The UK was well represented at the Genitourinary Cancers Symposium 2018, held in San Francisco, CA. In this video, Robert Jones, PhD, of the University of Glasgow & Beatson West of Scotland Cancer... Author: VJOncology Added: 02/19/2018 (Source: Oncology Tube)
Source: Oncology Tube - February 19, 2018 Category: Cancer & Oncology Source Type: podcasts

What does the 2-year follow-up tell us about the use of pembrolizumab for advanced bladder cancer?
Long-term follow-up data is the real determinant of the efficacy of novel therapies. Here, Robert Jones, PhD, of the University of Glasgow & Beatson West of Scotland Cancer Centre, Glasgow, UK, di... Author: VJOncology Added: 02/19/2018 (Source: Oncology Tube)
Source: Oncology Tube - February 19, 2018 Category: Cancer & Oncology Source Type: podcasts

Head-to-head: tolerability of enzalutamide vs. abiraterone acetate for metastatic CRPC
The approval of enzalutamide for the treatment of metastatic castration-resistant prostate cancer (mCRPC) provided an important life-extending drug. Now the sequencing and uses of enzalutamide are bei... Author: VJOncology Added: 02/16/2018 (Source: Oncology Tube)
Source: Oncology Tube - February 16, 2018 Category: Cancer & Oncology Source Type: podcasts

Differentiating aggressive vs. non-aggressive prostate cancer: the MiCheck GPC1 biomarker test
The addition of a new prostate cancer diagnostic test to inform clinicians and patients prior to the decision to biopsy would be beneficial, in conjunction with the traditional measures of PSA and DRE... Author: VJOncology Added: 02/16/2018 (Source: Oncology Tube)
Source: Oncology Tube - February 16, 2018 Category: Cancer & Oncology Source Type: podcasts

How will new NSAAs impact clinical practice in prostate cancer?
Previously, patients with nonmetastatic castration-resistant prostate cancer (nmCRPRC) and the clinicians treating them had no therapeutic options to delay disease progression. Now there are two new n... Author: VJOncology Added: 02/16/2018 (Source: Oncology Tube)
Source: Oncology Tube - February 16, 2018 Category: Cancer & Oncology Source Type: podcasts

Live long and PROSPER: enzalutamide for nmCRPC
There has previously been no approved treatment for nonmetastatic castration-resistant prostate cancer (nmCRPC), due to a lack of evidence that any drug would prevent disease progression in this popul... Author: VJOncology Added: 02/16/2018 (Source: Oncology Tube)
Source: Oncology Tube - February 16, 2018 Category: Cancer & Oncology Source Type: podcasts

Supporting young hematology researchers: training programs offered by EHA and ASH
This interview provides an exciting insight into the Translational Research Training in Hematology (TRTH) and the Clinical Research Training in Hematology (CRTH) programs, offered to junior hematology... Author: VJHemOnc Added: 02/16/2018 (Source: Oncology Tube)
Source: Oncology Tube - February 16, 2018 Category: Cancer & Oncology Source Type: podcasts

Novel methods to assess the effectiveness of chemotherapy in AML patients: MRD
It is extremely important to assess the long-term effects of chemotherapy in patients with acute myeloid leukemia (AML); however, with the knowledge of minimal residual disease, it is understood that ... Author: VJHemOnc Added: 02/16/2018 (Source: Oncology Tube)
Source: Oncology Tube - February 16, 2018 Category: Cancer & Oncology Source Type: podcasts

Randomized Phase III Trial of Atezolizumab + Bevacizumab The combination therapy proved efficacious, progression-free survival by PD-L1 group
Aly-Khan Lalani, MD from Dana-Farber Cancer Institute discusses the Randomized Phase III Trial of Atezolizumab + Bevacizumab The combination therapy proved efficacious, progression-free survival by PD... Author: Genitourinary-Cancer-Meeting Added: 02/15/2018 (Source: Oncology Tube)
Source: Oncology Tube - February 15, 2018 Category: Cancer & Oncology Source Type: podcasts

Microbiome Effects of Antibodies Can Linger for Up to 60 Days Push a start date to allow time between antibiotic use and immunotherapy
Aly-Khan Lalani, MD from Dana-Farber Cancer Institute discusses the Microbiome Effects of Antibodies Can Linger for Up to 60 Days Push a start date to allow time between antibiotic use and immunothera... Author: Genitourinary-Cancer-Meeting Added: 02/15/2018 (Source: Oncology Tube)
Source: Oncology Tube - February 15, 2018 Category: Cancer & Oncology Source Type: podcasts

Using Microbiome Transplantation or FMT for RCC They should still benefit from their given immunotherapy with additional supplements
Aly-Khan Lalani, MD from Dana-Farber Cancer Institute discusses tUsing Microbiome Transplantation or FMT for RCC They should still benefit from their given immunotherapy with additional supplements at... Author: Genitourinary-Cancer-Meeting Added: 02/15/2018 (Source: Oncology Tube)
Source: Oncology Tube - February 15, 2018 Category: Cancer & Oncology Source Type: podcasts

Systemic Therapy in Metastatic Renal Cell Carcinoma Antibiotic use does affect outcomes in patients
Aly-Khan Lalani, MD from Dana-Farber Cancer Institute discusses the Systemic Therapy in Metastatic Renal Cell Carcinoma Antibiotic use does affect outcomes in patients at the 2018 ASCO. Author: Genitourinary-Cancer-Meeting Added: 02/15/2018 (Source: Oncology Tube)
Source: Oncology Tube - February 15, 2018 Category: Cancer & Oncology Source Type: podcasts

Exciting randomized trials for mesothelioma: checkpoint inhibitor monotherapies and vinorelbine
Only one treatment for malignant mesothelioma has been approved since 2003 and rates of the disease are rising worldwide; thus, new treatments must be found. Here, Dean Fennell, PhD, FRCP, of Universi... Author: VJOncology Added: 02/13/2018 (Source: Oncology Tube)
Source: Oncology Tube - February 13, 2018 Category: Cancer & Oncology Source Type: podcasts